ALGENESS VL Injection Solution for

What is ALGENESS VL

ALGENESS VL is a dermal filler based on a patented formula containing purified agarose Type I, designed for soft tissue augmentation and facial contouring. Unlike many traditional dermal fillers made from hyaluronic acid or synthetic polymers, ALGENESS is unique in that it is composed of a 100% natural, biocompatible polysaccharide derived from red algae.

• Primary Use: Non-surgical aesthetic procedures, including:
  • Facial volume restoration
  • Correction of moderate-to-deep wrinkles and folds
  • Chin and cheek augmentation
  • Nasal bridge corrections
• Ideal Candidates: Adults seeking non-permanent but long-lasting facial rejuvenation
• Composition: Agarose Type I in a pre-filled syringe with no cross-linking chemicals, making it a biodegradable and resorbable product
• Advantage: Minimal swelling, more predictable placement, and immediate visible results

ALGENESS VL stands out for its excellent safety profile and mechanical stability, offering precise results with a reduced risk of inflammatory response. It is particularly appreciated by professionals looking for natural and biointegrative alternatives to synthetic fillers.

How to use ALGENESS VL

ALGENESS VL is designed for professional use only and should be administered by trained healthcare providers experienced in facial aesthetics and dermal filler injections.

• Route of Administration: Intradermal or subdermal injection
• Injection Technique:
  • Linear threading
  • Depot (bolus) injection
  • Fanning or cross-hatching techniques depending on the treatment area
• Injection Sites:
  • Midface (cheeks)
  • Nasal dorsum (nose bridge)
  • Chin and jawline
  • Nasolabial folds
• Preparation:
  • Clean and disinfect the treatment area thoroughly
  • Optional use of topical anesthetic (though many patients find ALGENESS tolerable without it)
• Post-Injection Care:
  • Apply cold compress if needed to reduce swelling
  • Avoid makeup, alcohol, and strenuous activity for 24 hours
  • Do not massage the area unless advised by the injector

Results are typically visible immediately, with further refinement as mild swelling resolves. Follow-up visits may be scheduled to evaluate satisfaction and determine if additional filler is needed.

Mode of Action ALGENESS VL

ALGENESS VL works through a purely physical mechanism by occupying space and integrating into the dermal matrix. It is a volumizing filler that does not rely on chemical cross-linking or biological receptor binding like some other fillers.

• Volumization and Structural Support:
  • Agarose Type I forms a stable three-dimensional gel network when injected
  • This gel exerts a lifting and contouring effect by physically occupying subdermal space
• Natural Integration:
  • The agarose gel gradually integrates with surrounding tissues without inflammation
  • Provides a scaffold for tissue rehydration and smoothing of wrinkles
• Biodegradability:
  • Agarose is naturally degraded by the body through enzymatic and mechanical processes
  • Complete resorption occurs over several months, typically 8–12 months depending on placement and patient factors
• Hydrophilicity: Unlike hyaluronic acid, agarose is less hydrophilic, leading to minimal swelling and more precise volumetric control

Because ALGENESS does not contain any cross-linked polymers or chemical additives, its safety and tolerability are enhanced, making it suitable even for patients with sensitivity to synthetic fillers.

ALGENESS VL Interactions ALGENESS VL

Although ALGENESS VL is biologically inert and well-tolerated, there are still considerations when used in conjunction with other aesthetic treatments or medications.

• Drug Interactions:
  • No known systemic drug interactions due to its non-pharmacological, physical mechanism
• Procedure-Based Interactions:
  • Should not be injected into areas previously treated with permanent fillers
  • Caution advised when combining with laser resurfacing or chemical peels in the same area (may increase risk of inflammation)
• Concurrent Treatments:
  • Can be combined safely with botulinum toxin injections, but sequencing matters (Botox first, filler 1–2 weeks later)
• Immunosuppressive Drugs:
  • Theoretical risk of altered healing or infection response if used in immunocompromised individuals

While systemic drug interactions are unlikely due to ALGENESS’ inert nature, clinicians should assess the patient’s full medical and treatment history before proceeding with injections.

Dosage of ALGENESS VL

Dosage with ALGENESS VL is individualized and based on aesthetic goals, treatment area, and the experience of the practitioner. Each pre-filled syringe contains 1.4 mL of product, and a treatment may require one or both syringes depending on volume deficit and patient needs.

• Standard Dosage Guidelines:
  • Nasolabial folds: 0.3–0.8 mL per side
  • Chin enhancement: 0.5–1.2 mL total
  • Midface/cheeks: 1–2 mL total
  • Nose reshaping: 0.3–0.6 mL
• Administration Frequency: One treatment session usually lasts 8–12 months. Repeat treatments can be done as needed.
• Maximum Safe Dose: No formal systemic dose limit, but overcorrection should be avoided.
• Injection Volume Control: Small, incremental injections are preferred to achieve precision and avoid overfilling.

The choice of injection depth and volume should be tailored to the patient's anatomy and desired aesthetic outcome. A conservative approach is often recommended, with the option for touch-ups at follow-up visits.

Possible side effects of ALGENESS VL

ALGENESS VL has an excellent safety profile due to its natural and non-chemical composition. However, as with any dermal filler, some local side effects may occur, especially at the injection site.

• Common Side Effects (usually transient):
  • Redness (erythema)
  • Swelling
  • Mild pain or tenderness
  • Bruising
  • Itching
• Less Common Side Effects:
  • Nodule formation or localized firmness
  • Asymmetry or overcorrection
• Rare Complications:
  • Infection at the injection site
  • Vascular occlusion (if injected improperly into a blood vessel)
  • Hypersensitivity reaction (extremely rare with agarose)
• Management: Most side effects resolve within 1–7 days

Immediate medical evaluation is advised if signs of vascular compromise (pain, blanching, discoloration) or severe allergic response occur. These are rare but serious complications that require prompt treatment.

ALGENESS VL Contraindications ALGENESS VL

While ALGENESS VL is generally safe, it is not suitable for every patient or every clinical situation. It should be avoided in certain contraindicated cases to prevent complications.

• Absolute Contraindications:
  • Known allergy to agarose or any excipients in the formula
  • Active skin infections or inflammation at the intended injection site (e.g., herpes simplex, acne)
  • History of severe anaphylaxis or allergic reactions to injectable products
  • Permanent filler in the same anatomical region
• Relative Contraindications (caution advised):
  • Autoimmune disorders
  • Bleeding disorders or patients on anticoagulant therapy
  • Immunocompromised patients
  • Pregnancy and breastfeeding (not studied, avoid as precaution)

A comprehensive medical history and facial assessment should be conducted before any filler treatment to determine candidacy and ensure safety.

Storage of ALGENESS VL

Proper storage of ALGENESS VL is essential to preserve its physical integrity and sterility.

• Storage Temperature: Store at 2°C to 25°C (36°F to 77°F)
• Avoid Freezing: Do not freeze the product as this may alter its gel structure
• Packaging: Keep in original packaging to protect from light and contamination
• Sterility: Each syringe is single-use only. Do not attempt to reuse or resterilize
• Expiration: Observe the expiry date on the carton and syringe label
• Handling: Inspect syringe before use. Do not use if packaging is damaged or if the product appears cloudy or discolored

Proper storage ensures the effectiveness, safety, and consistency of ALGENESS VL. Always follow the manufacturer's specific guidelines for storage and handling provided in the product leaflet.